Neos Therapeutics, Inc. (NASDAQ:NEOS) headquartered in Grand Prairie, will host a conference call for the investment community to discuss the 3Q20 financial results on 9th November 2020 at 8:30 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.neostx.com
Earnings Expectation
Neos Therapeutics, Inc. is reporting third quarter earnings results on Monday 9th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.05 per share from $ 15.47 million in revenue. For the full year, analysts predict revenues of $ 62.72 million, while looking forward to loss of $ 0.31 per share.
Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for treating of ADHD; Adzenys ER amphetamine to treat ADHD; and generic Tussionex hydrocodone and chlorpheniramine for cough and upper respiratory symptoms of a cold.
